These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27769101)

  • 1. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
    Kang SH; Kang K; Jong Eun Y; Lee YS; Kim TS; Yoo YJ; Suh SJ; Yoon EL; Jung YK; Kim JH; Seo YS; Yim HJ; Byun KS
    J Med Virol; 2017 May; 89(5):849-856. PubMed ID: 27769101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
    Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
    World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
    Kim JH; Lee SJ; Joo MK; Kim CH; Choi JH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Dig Dis Sci; 2009 Jul; 54(7):1572-7. PubMed ID: 18975080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
    Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
    J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
    Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
    J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    Kim MN; Park JY; Ahn SH; Kim BK; Kim SU; Kim DY; Han KH
    J Med Virol; 2017 Jan; 89(1):85-90. PubMed ID: 27357598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients.
    Jin YJ; Kim KM; Yoo DJ; Shim JH; Lee HC; Chung YH; Lee YS; Suh DJ
    Virol J; 2012 Oct; 9():239. PubMed ID: 23078793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B.
    Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2016 Jan; 67(1):28-34. PubMed ID: 26809629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
    Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
    Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response.
    Gara N; Tana MM; Kattapuram M; Auh S; Sullivan L; Fryzek N; Walter M; Umarova R; Zhao X; Cloherty G; Doo E; Heller T; Liang TJ; Ghany MG
    Hepatol Commun; 2021 Nov; 5(11):1888-1900. PubMed ID: 34558806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
    Lu HY; Zhuang LW; Yu YY; Si CW
    J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
    Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
    Lu J; Li J; Liu Y; Ren S; Cao Z; Jin Y; Ma L; Shen C; Chen X
    PLoS One; 2015; 10(11):e0141072. PubMed ID: 26524467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.
    Lee KM; Cho SW; Kim SW; Kim HJ; Hahm KB; Kim JH
    J Viral Hepat; 2002 May; 9(3):208-12. PubMed ID: 12010509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.